Navigation Links
Neurobiological Technologies Receives Nasdaq Closing Bid Price Notification
Date:9/17/2009

EMERYVILLE, Calif., Sept. 17 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII) ("NTI") announced today that, on September 15, 2009, it received a letter from The Nasdaq Stock Market indicating that the bid price of NTI's common stock has closed below $1.00 per share for 30 consecutive business days. The letter indicated that a closing bid price below $1.00 per share is a deficiency under Nasdaq's requirements for continued listing pursuant to Marketplace Rule 5550(a)(2). The letter from Nasdaq further stated that, under Marketplace Rule 5810(c)(3)(A), NTI will be provided 180 calendar days, or until March 15, 2010, to regain compliance with Marketplace Rule 5550(a)(2). To regain compliance, the bid price of NTI's common stock must close at $1.00 per share or more for a minimum of 10 consecutive business days.

The letter also stated that on March 15, 2010, if NTI meets the Nasdaq Capital Market initial inclusion criteria set forth in Marketplace Rule 5505, except for the bid price requirement, it may be provided with an additional 180 calendar day period to demonstrate compliance. On March 15, 2010, if NTI is not eligible for an additional compliance period, Nasdaq Staff will provide written notification that NTI's securities will be delisted. Upon such notice, NTI may appeal the Nasdaq Staff's Determination to a Listing Qualifications Panel, pursuant to the procedures set forth in the Nasdaq Marketplace Rule 5800 Series.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc. is a biopharmaceutical company historically focused on developing investigational drugs for central nervous system conditions. On September 8, 2009, the Company filed a preliminary proxy statement relating to its intention to call a special
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Neurobiological Technologies Announces Termination of its License and Cooperation Agreement with Merz and Childrens Medical Center
2. Neurobiological Technologies Announces Hiring of Advisor to Seek Sale of Company
3. Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results
4. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
5. Neurobiological Technologies Announces Suspension of Viprinex Development
6. Neurobiological Technologies Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
7. Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results
8. Neurobiological Technologies to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York on November 10
9. Neurobiological Technologies Sets Date for First Quarter Financial Results
10. Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine
11. Neurobiological Technologies to Present at the BIO Investor Forum in San Francisco on October 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015 /PRNewswire/ - SQI Diagnostics Inc. ... sciences company that develops and commercializes proprietary technologies and ... and operational results for the second fiscal quarter ended ... the Company continued to advance business with our existing ... Morris , President and CEO of SQI. "The delivery ...
(Date:5/21/2015)... San Francisco, CA (PRWEB) May 21, 2015 ... microbiome sequencing, has announced a partnership with PicnicHealth, ... records for patients. Participants diagnosed with Inflammatory Bowel ... as well as a complementary uBiome research kit. ... Summer 2014. , For more ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation ... development company specializing in oncology, today announced positive ... trial with aldoxorubicin for the treatment of unresectable ... cancer.  The open-label, multisite trial is designed to ... in patients whose tumors have progressed following prior ...
(Date:5/21/2015)... 2015 Tunnell Consulting, Inc. ... as senior statistician and Principal, a position to which ... the management and analysis of complex and large data ... , “We’re delighted to have Julia join the Tunnell ... said Dr. Philippe Cini, Group Vice President and leader ...
Breaking Biology Technology:SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2
... NicOx S.A.,(Euronext Paris: COX) today announced that ... be leaving the company on May 30th,to become ... company. Damian,s responsibilities will be assumed by,Sanjiv Sharma, ... Business Development., Michele Garufi, Chairman and CEO ...
... 26 Sidec announces that the application,form for ... at Sidec,s,homepage. The winning application will be offered ... Protein Tomography(TM) study is,typically in the range of ... funded by,Sidec., (Logo: http://www.newscom.com/cgi-bin/prnh/20080220/294289 ), ...
... Europe, Less Screening and Treatment, and an Apparent Higher Prevalence ... Hip Fracture Than in North America and Australia, BARCELONA, ... in four women surveyed from Europe, North America, and,Australia reported ... 45,years. Among women considered to be at high risk for ...
Cached Biology Technology:NicOx Announces Departure of Damian Marron for CEO Position 2The Protein Tomography(TM) Award Now Published on Sidec's Homepage 2Global Study Reveals Differences in Standard of Care for Osteoporosis Across the World 2Global Study Reveals Differences in Standard of Care for Osteoporosis Across the World 3Global Study Reveals Differences in Standard of Care for Osteoporosis Across the World 4
(Date:5/20/2015)... , May 20, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the addition ... the Global Iris Recognition Market"  report ... , ,This research service analyses trends ... the government and commercial sectors, globally. ...
(Date:5/19/2015)... 19, 2015 Research ... addition of the  "Genetic Testing Market Outlook ... http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic Testing ... of the current and future genetic testing ... their working principles and types are covered ...
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated ... human interface solutions, today announced the appointment of ... and Chief Financial Officer, reporting to Rick ... Synaptics, current Chief Financial Officer, Kathleen Bayless ... Mr. Ali brings extensive financial ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... by someone listening to their i-Pod loud enough for you ... is going to become the next big epidemic affecting our ... too late to treat. In addition to loud noise, ... in humans due to loss or faulty development of the ...
... team of UCSB researchers, in collaboration with colleagues ... Gatos, California, has designed a novel pulsed microjet system ... the pain or bruising that deeper penetration injection systems ... Proceedings of the National Academy of Sciences. , ...
... giants, but many dinosaurs apparently had genomes no larger than ... linked bone cell and genome size among living species and ... of 31 species of extinct dinosaurs and birds, whose bone ... The researchers, at Harvard University and the University of Reading, ...
Cached Biology News: Study shows isolation of stem cells may lead to a treatment for hearing loss 2 Study shows isolation of stem cells may lead to a treatment for hearing loss 3Researchers design pulsed mircrojet system to deliver protein drugs without pain or bruising 2Despite their heft, many dinosaurs had surprisingly tiny genomes 2